English  |  正體中文  |  简体中文  |  Items with full text/Total items : 1657/1756
Visitors : 3812587      Online Users : 152
RC Version 5.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister

Please use this identifier to cite or link to this item: http://140.112.115.32:8080/ir/handle/987654321/2770

Title: Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP
Authors: Wan-Jung Lu;Nen-Chung Chang;Thanasekaran Jayakumar;Jiun-Cheng Liao;Mei-Jiun Lin;Shwu-Huey Wang;Duen-Suey Chou;Philip Aloysius Thomas;Joen-Rong Sheu
Contributors: 視光學系
Keywords: CME-1;Cyclic AMP;Platelet activation;Polysaccharide
Date: 2014-12-01
Issue Date: 2025-08-01 15:07:01 (UTC+8)
Abstract: Introduction
CME-1, a novel water-soluble polysaccharide, was purified from the mycelia of Cordyceps sinensis, and its chemical structure was characterized to contain mannose and galactose in a ratio of 4:6 (27.6 kDa). CME-1 was originally observed to exert a potent inhibitory effect on tumor migration and a cytoprotective effect against oxidative stress. Activation of platelets caused by arterial thrombosis is relevant to various cardiovascular diseases (CVDs). However, no data are available concerning the effects of CME-1 on platelet activation. Hence, the purpose of this study was to examine the ex vivo and in vivo antithrombotic effects of CME-1 and its possible mechanisms in platelet activation.
Methods
The aggregometry, immunoblotting, flow cytometric analysis and platelet functional analysis were used in this study.
Results
CME-1 (2.3-7.6 μM) exhibited highly potent activity in inhibiting human platelet aggregation when stimulated by collagen, thrombin, and arachidonic acid but not by U46619. CME-1 inhibited platelet activation accompanied by inhibiting Akt, mitogen-activated protein kinases (MAPKs), thromboxane B2 (TxB2) and hydroxyl radical (OH●) formation. However, CME-1 interrupted neither FITC-triflavin nor FITC-collagen binding to platelets. CME-1 markedly increased cyclic AMP levels, but not cyclic GMP levels, and stimulated vasodilator-stimulated phosphoprotein (VASP) phosphorylation. SQ22536, an inhibitor of adenylate cyclase, but not ODQ, an inhibitor of guanylate cyclase, obviously reversed the CME-1-mediated effects on platelet aggregation and vasodilator-stimulated phosphoprotein (VASP), Akt, p38 MAPK phosphorylation, and TxB2 formation. CME-1 substantially prolonged the closure time of whole blood and the occlusion time of platelet plug formation.
Conclusion
This study demonstrates for the first time that CME-1 exhibits highly potent antiplatelet activity that may initially activate adenylate cyclase/cyclic AMP and, subsequently, inhibit intracellular signals (such as Akt and MAPKs), ultimately inhibiting platelet activation. This novel role of CME-1 indicates that CME-1 exhibits high potential for application in treating and preventing CVDs.
Relation: Thrombosis Research, 134(6), 1301-1310. https://doi.org/10.1016/j.thromres.2014.09.023
Appears in Collections:[視光學系] 期刊論文

Files in This Item:

File SizeFormat
index.html0KbHTML9View/Open


All items in MMUIR are protected by copyright, with all rights reserved.

 


DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback